Loading…
Loading…
IBOGF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for IBOGF and 80,000+ other tickers.
See exactly how IBOGF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IBOGF and 80,000+ other tickers.
Universal Ibogaine Inc., a life sciences enterprise, focuses on developing, acquiring, and operating addiction treatment centers across Canada. The company is additionally preparing to launch clinical trials aimed at researching ibogaine's potential therapeutic applications for addiction. Its principal corporate offices are based in Calgary, Canada.
Calgary, AB – TheNewswire - January 19, 2026 – Universal Ibogaine Inc. ( TSXV:IBO ) (“ UI ” or the “ Company ”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Management Cease Trade Order (“MCTO”)
Calgary, AB – TheNewswire - January 2, 2026 – Universal Ibogaine Inc. ( TSXV:IBO ) (“ UI ” or the “ Company ”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Management Cease Trade Order (“MCTO”)
Calgary, AB – TheNewswire - December 18, 2025 – Universal Ibogaine Inc. ( TSXV:IBO ) (“ UI ” or the “ Company ”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following initial bi-weekly default status report update: Management Cease Trade Order (“MCTO”)
Calgary, AB – December 2, 2025 – TheNewswire – Universal Ibogaine Inc. ( TSXV:IBO ) (“ UI ” or the “ Company ”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises of the following additional points related to its prior News Release of November 25, 2025 regarding its application to the Alberta Securities Commission (the “ ASC ”, the Company's Principal Regulator) for a Management Cease Trade Order (“ MCTO ”): The Company is not currently subject to any insolvency proceedings;
Calgary, AB – TheNewswire - November 25, 2025 – Universal Ibogaine Inc. ( TSXV:IBO ) (“ UI ” or the “ Company ”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it has made an application to the Alberta Securities Commission (as Principal Regulator) and the British Columbia Securities Commission, to approve a temporary management case trade order (“ MCTO ”) under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults (“ NP 12-203 ”), which, if granted, will prohibit trading securities of the Company by the Chief Executive Officer and Chief Financial Officer (position currently vacant) of the Company until such time as the Required Filings (defined below) and all continuous disclosure requirements have been filed by the Company, and the MCTO has been lifted. During the period in which the MCTO is in effect, the general public will continue to be able to trade in the Company's listed common shares. The MCTO application has been made but there is no guarantee or assurance that the MCTO will be granted. The Company will be unable to file its audited consolidated financial statements for the financial year ended July 31, 2025 (the “ Financial Statements ”) and the related management's discussion and analysis (the “ MD&A ”) and Chief Executive Officer and Chief Financial Officer certificates for this period (collectively, with the Financial Statements, the “ Required Filings ”) before the filing deadline of November 28, 2025 (the “ Filing Deadline ”).